Diuretics

Acarbose, diuretics

The combined active ingredient with acarbose may cause hyperglycaemia, what may attenuate the acarbose effects. Monitorization of the blood-sugar concentration is recommended

ACE inhibitors, diuretics

Excessive reductions in blood pressure, especially in patients in whom diuretic therapy was recently instituted, have been

ACE inhibitors, loop diuretics

Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor.

ACE inhibitors, potassium-sparing diuretics ---> SmPC of [fosinopril] of eMC

Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.

Acebutolol, diuretics

Risk of hypotension and bradycardia

Aceclofenac [1], diuretics ---> SmPC of [1] of eMC

Aceclofenac, like other NSAIDs, may inhibit the activity of diuretics. Diuretics can increase the risk of nephrotoxicity of NSAIDs

Aceclofenac [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

When concomitant administration of diclofenac with potassium-sparing diuretics is employed, serum potassium should be monitored.

Acemetacine, diuretics

Reduced diuretic effect. Diuretic can increase the risk of nephrotoxicity of the NSAID

Acemetacine, potassium-sparing diuretics

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Acetazolamide, diuretics

The co-administration with other diuretics (greater diuresis) may cause severe hypokalemia and hyperuricemia

Acetylsalicylic acid [1], diuretics ---> SmPC of [1] of eMC

NSAIDs may decrease the antihypertensive effects of diuretics and other antihypertensive agents.

Acetylsalicylic acid, loop diuretics

Decreased effects of loop diuretic

Aclidinium/formoterol [1], loop diuretics ---> SmPC of [1] of EMA

Concomitant treatment of aclidinium/formoterol with non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore caution is advised in their concomitant use

Aclidinium/formoterol [1], non-potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant treatment of aclidinium/formoterol with non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore caution is advised in their concomitant use

ACTH, loop diuretics ---> SmPC of [chlortalidone] of eMC

The hypokalaemic effect of diuretics may be potentiated by ACTH

Adrenaline [1], diuretics ---> SmPC of [1] of eMC

Drugs which cause potassium loss (corticosteroids, potassium-depleting diuretic, aminophylline, theophylline) increase the risk of hypokalemia.

Adrenaline, loop diuretics

Decreased effect of pressor amine

AIIRA, potassium-sparing diuretics ---> SmPC of [spironolactone] of eMC

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Aliskiren [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of other agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium levels may lead to increases in serum potassium.

Aliskiren/amlodipine [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of aliskiren/amlodipine and other agents that increase serum potassium levels may lead to increases in serum potassium. Caution is advisable.

Aliskiren/amlodipine/hydrochlorothiazide [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of aliskiren with other agents that increase serum potassium levels may lead to increases in serum potassium. If co-medication is considered necessary, caution is advisable.

Aliskiren/hydrochlorothiazide [1], loop diuretics ---> SmPC of [1] of EMA

The potassium-depleting effect of hydrochlorothiazide on serum potassium would be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia

Aliskiren/hydrochlorothiazide [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of aliskiren with other agents that increase serum potassium levels may lead to increases in serum potassium. If co-medication is considered necessary, caution is advisable.

Allopurinol [1], diuretics ---> SmPC of [1] of eMC

Patients under treatment for hypertension or cardiac insufficiency, for example with diuretics, may have some concomitant impairment of renal function and allopurinol should be used with care in this group.

Allopurinol/lesinurad [1], diuretics ---> SmPC of [1] of EMA

An increased risk of hypersensitivity has been reported when allopurinol is given with diuretics, in particular thiazides, especially in renal impairment

Alogliptin/metformin [1], diuretics ---> SmPC of [1] of EMA

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also hyperglycemic effect.

Amikacine [1], strong diuretic agents ---> SmPC of [1] of eMC

The risk of ototoxicity is increased when amikacin is used in conjunction with rapidly acting diuretic drugs, particularly when the diuretic is administered intravenously.

Amiloride, potassium-sparing diuretics

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Amiloride/hydrochlorothiazide, diuretics

The hypotensive effect of amiloride/hydrochlorothiazide can be enhanced by other diuretic agents

Amiloride/hydrochlorothiazide, non-potassium-sparing diuretics

The co-administration of amiloride/hydrochlorothiazide and kaliuretic diuretics (e. g. furosemide) may increase the potassium loss

Amiloride/hydrochlorothiazide, potassium-sparing diuretics

Concomitant administration of potassium-sparing diuretics or potassium salts may increase the risk of hypercaliemia

Aminobenzoate potassium, potassium-sparing diuretics

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Aminoglycoside antibiotics, loop diuretics

The co-administration may enhance the ototoxicity and/or nephrotoxicity

Aminoglycoside antibiotics, strong diuretic agents ---> SmPC of [bumetanide] of eMC

Ototoxic effects of aminoglycosides may be increased during the treatment with strong diuretics

Aminophylline, diuretics

There is an increased risk of hypokalaemia when theophylline derivatives are given with diuretics

Aminophylline, non-potassium-sparing diuretics

There is an increased risk of hypokalaemia when theophylline derivatives are given with diuretics

Amiodarone, non-potassium-sparing diuretics

Caution should be exercised over combined therapy with diuretics which may also cause hypokalaemia and/or hypomagnesaemia

Amisulpride, diuretics

Concomitant use of amisulpride with drugs inducing hypokaliemia is not recommended

Amitriptyline [1], diuretics ---> SmPC of [1] of eMC

Increased risk of postural hypotension.

Amlodipine [1], diuretics ---> SmPC of [1] of eMC

The blood pressure lowering effect can be increased by concomitant use

Amlodipine/valsartan [1], diuretics ---> SmPC of [1] of EMA

The blood pressure lowering effect can be increased by concomitant use

Amlodipine/valsartan [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

If a medicinal product that affects potassium levels is to be prescribed in combination with valsartan, monitoring of potassium plasma levels is advised.

Amlodipine/valsartan/hydrochlorothiazide [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.

Amphotericin, loop diuretics ---> SmPC of [chlortalidone] of eMC

The hypokalaemic effect of diuretics may be potentiated by amphotericin

Antidepressants, diuretics ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

The hyponatraemic effect of diuretics may be intensified by concomitant administration of antidepressants. Caution is indicated in long-term administration of these medicinal products.

Antidiabetics, loop diuretics

Decreased hypoglycaemic effect

Antiepileptics, diuretics ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

The hyponatraemic effect of diuretics may be intensified by concomitant administration of antiepileptics. Caution is indicated in long-term administration of these medicinal products.

Antihypertensives, diuretics

Additive hypotensive effect

Antihypertensives, loop diuretics

Enhancement of hypotensive effect

Antihypertensives, potassium-sparing diuretics ---> SmPC of [eplerenone] of eMC

Potassium-sparing diuretics may potentiate the effect of anti-hypertensive agents

Arsenic trioxide [1], loop diuretics ---> SmPC of [1] of EMA

Caution is advised when arsenic trioxide is coadministered with other medicinal products known to cause QT/QTc interval prolongation

Atenolol, diuretics

Concomitant use of atenolol with antihypertensive agents as well as other drugs with blood pressure lowering potential may increase the risk of hypotension.

Atenolol/chlortalidone, diuretics

Enhanced antihypertensive effect

Atenolol/nifedipine, diuretics

Atenolol/nifedipine may increase the blood pressure lowering and heart rate modulating effects of concomitant applied antihypertensives (diuretics)

Atomoxetine, non-potassium-sparing diuretics

There is the potential for an increased risk of QT interval prolongation when atomoxetine is administered with drugs that cause electrolyte imbalance (such as thiazide diuretics)

Atracurium [1], diuretics ---> SmPC of [1] of eMC

As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with diuretics

Azilsartan medoxomil [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of serum potassium should be undertaken as appropriate

Azilsartan [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Bambuterol [1], loop diuretics ---> SmPC of [1] of eMC

Hypokalemia may result from beta2-agonist therapy and may be potentiated by concomitant treatment with diuretics

Barbiturates, loop diuretics

Enhancement of hypotensive effect

Beclometasone [1], non-potassium-sparing diuretics ---> SmPC of [1] of eMC

The hypokalaemic effect of diuretics may be potentiated by corticosteroids

Beclometasone/formoterol/glycopyrronium [1], diuretics ---> SmPC of [1] of EMA

Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalaemic effect of beta2-agonists

Benazepril, diuretics

Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor.

Benazepril, potassium-sparing diuretics

Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.

Bendroflumethiazide, diuretics

The co-administration may increase the antihypertensive effects

Beta2-adrenergic agonists, non-potassium-sparing diuretics ---> SmPC of [umeclidinium/vilanterol] of EMA

Concomitant hypokalaemic treatment with non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Betablockers, diuretics

When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.

Betaxolol, diuretics

The combination may cause strong hypotension

Biphosphonates, loop diuretics ---> SmPC of [zoledronic acid] of EMA

Caution is advised when bisphosphonates are administered with loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required

Bisacodyl [1], diuretics ---> SmPC of [1] of eMC

The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of bisacodyl are taken.

Bisacodyl [1], loop diuretics ---> SmPC of [1] of eMC

The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of bisacodyl are taken.

Bisacodyl [1], non-potassium-sparing diuretics ---> SmPC of [1] of eMC

The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of bisacodyl are taken.

Bumetanide, diuretics

Bumetanide may potentiate the effects of antihypertensive drugs.

Bupivacaine/meloxicam [1], diuretics ---> SmPC of [1] of EMA

Patients on diuretics should be monitored following treatment with Zynrelef for signs of worsening renal function, in addition to assuring diuretic efficacy, including antihypertensive effects.

Canagliflozin [1], diuretics ---> SmPC of [1] of EMA

Canagliflozin may add to the effect of diuretics and may increase the risk of dehydration and hypotension

Canagliflozin, loop diuretics ---> SmPC of [canagliflozin/metformin] of EMA

Canagliflozin is not recommended for use in patients receiving loop diuretics.

Canagliflozin/metformin [1], diuretics ---> SmPC of [1] of EMA

Canagliflozin may add to the effect of diuretics and may increase the risk of dehydration and hypotension. Diuretics (especially loop diuretics) may increase the risk of lactic acidosis associated with metformin.

Canagliflozin/metformin [1], loop diuretics ---> SmPC of [1] of EMA

Canagliflozin is not recommended for use in patients receiving loop diuretics.

Candesartan cilexetil [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels.

Candesartan [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels.

Captopril [1], loop diuretics ---> SmPC of [1] of eMC

Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with captopril

Captopril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.

Carbamazepine, diuretics

Increased risk of hyponatraemia when diuretics given with carbamazepine

Carbenoxolone, loop diuretics ---> SmPC of [chlortalidone] of eMC

The hypokalaemic effect of diuretics may be potentiated by carbenoxolone

Carboplatin [1], loop diuretics ---> SmPC of [1] of eMC

Concurrent therapy of carboplatin with diuretics is not recommended, since this may lead to increased or exacerbated toxicity due to carboplatin induced changes in renal clearance of these substances.

Carboplatin, diuretics

May increase or exacerbate toxicity due to carboplatin induced changes in renal clearance

Cardiac glycosides, non-potassium-sparing diuretics

The co-administration of cardiac glycosides and drugs that cause potassium and magnesium loss may enhance the effects and adverse reactions of cardiac glycosides

Cefaclor, loop diuretics

Increased risk of nephrotoxicity

Cefadroxil, loop diuretics

Treatment with Cefadroxil in combination with high-dose loop diuretics should be avoided since such combinations can potentiate nephrotoxic effects.

Cefazolin, strong diuretic agents

The combination of cefazolin with nephrotoxic drugs may potentiate the nephrotoxicity. Monitoring of renal function is recommended

Cefixime, diuretics

A treatment with high doses of cephalosporins in patients receiving diuretics may cause renal function impairment

Cefotaxime [1], loop diuretics ---> SmPC of [1] of eMC

The combination of cefotaxime with nephrotoxic drugs may potentiate the nephrotoxicity. Monitoring of renal function is recommended

Cefotaxime [1], strong diuretic agents ---> SmPC of [1] of eMC

The combination of cefotaxime with nephrotoxic drugs may potentiate the nephrotoxicity. Monitoring of renal function is recommended

Cefpodoxime, strong diuretic agents

Increased risk of renal insufficiency

Ceftazidime, strong diuretic agents

Increased risk of renal insufficiency

Ceftriaxone [1], strong diuretic agents ---> SmPC of [1] of eMC

No impairment of renal function has so far been observed after concurrent administration of large doses of ceftriaxone and potent diuretics

Cefuroxime, loop diuretics

Increased risk of renal insufficiency

Cefuroxime, strong diuretic agents

A treatment with high doses of cephalosporins should be done with caution in patients receiving potent diuretics, because renal function impairment cannot be excluded

Celecoxib [1], diuretics ---> SmPC of [1] of EMA

Reduced diuretic and antihypertensive effect of diuretic. Diuretic can increase the risk of nephrotoxicity of the NSAID

Cephalexin [1], loop diuretics ---> SmPC of [1] of EMA

Cephalosporins may have an increased risk of nephrotoxicity in the presence of loop diuretics

Cephalosporins, loop diuretics ---> SmPC of [cephalexin] of eMC

Cephalosporins may have an increased risk of nephrotoxicity in the presence of loop diuretics

Cephalosporins, strong diuretic agents ---> SmPC of [ceftazidime/avibactam] of EMA

Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function

Chloral hydrate, non-potassium-sparing diuretics

Concomitant use of chloral hydrate with drugs that can cause hypokaliemia should be avoided

Chlorprothixene, non-potassium-sparing diuretics

The co-administration of chlorprothixene with drugs that can cause hypokaliemia should be avoided

Chlortalidone, diuretics

The co-administration may increase the antihypertensive effects

Cilazapril [1], loop diuretics ---> SmPC of [1] of eMC

Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with cilazapril

Cilazapril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.

Cisatracurium [1], diuretics ---> SmPC of [1] of eMC

Diuretics increase the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents

Cisplatin [1], loop diuretics ---> SmPC of [1] of eMC

Concomitant administration of cisplatin and ototoxic medicinal products will potentiate the toxic effect of cisplatin on auditory function.

Clomipramine [1], diuretics ---> SmPC of [1] of eMC

Diuretics may lead to hypokalemia, which increases the risk of QTc prolongation and Torsade de Pointes

Clonazepam, diuretics

Enhanced hypotensive effect

Clonidine [1], diuretics ---> SmPC of [1] of eMC

Concurrent administration of antihypertensive agents may lead to an increased hypotensive effect.

Clopamide, diuretics

Increased hypotensive effect

Clopidogrel/acetylsalicylic acid [1], diuretics ---> SmPC of [1] of EMA

Interactions with diuretics and higher (anti-inflammatory) doses of ASA have been reported

Corticosteroids, diuretics

Effects of diuretics are antagonized by corticosteroids

Corticosteroids, non-potassium-sparing diuretics ---> SmPC of [deflazacort] of eMC

The hypokalaemic effect of diuretics may be potentiated by corticosteroids

Cotrimoxazole [1], diuretics ---> SmPC of [1] of eMC

Elderly patients concurrently receiving diuretics, mainly thiazides, there is an increased risk of thrombocytopenia with or without purpura.

Curare-type muscle relaxants [1], diuretics ---> SmPC of [1] of eMC

Diuretics potentiate the action of curare derivatives

Curare-type muscle relaxants, loop diuretics

Effect enhancement of both active principles

Cyclizine, loop diuretics

The co-administration may mask ototoxicity symptoms

Cyclosporine [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Caution is required with concomitant use of ciclosporin with potassium-sparing medicinal products or potassium-containing medicinal products since they may lead to significant increases in serum potassium

Dapagliflozin [1], loop diuretics ---> SmPC of [1] of EMA

This medicinal product may add to the diuretic effect of loop diuretics and may increase the risk of dehydration and hypotension

Dapagliflozin/metformin [1], diuretics ---> SmPC of [1] of EMA

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also hyperglycemic effect.

Dapagliflozin/metformin [1], loop diuretics ---> SmPC of [1] of EMA

This medicinal product may add to the diuretic effect of loop diuretics and may increase the risk of dehydration and hypotension

Deflazacort [1], non-potassium-sparing diuretics ---> SmPC of [1] of eMC

Corticosteroids may exacerbate the hypokalaemia associated with thiazide use.

Delapril [1], diuretics ---> SmPC of [1] of eMC

Excessive reductions in blood pressure, especially in patients in whom diuretic therapy was recently instituted, have been reported with ACE inhibitors.

Delapril, potassium-sparing diuretics

Concomitant administration of potassium-sparing diuretics or potassium salts may increase the risk of hypercaliemia

Dexibuprofen [1], loop diuretics ---> SmPC of [1] of eMC

Concurrent use of an NSAID and a diuretic may increase the risk of renal failure secondary to a reduction in renal blood flow.

Dexibuprofen [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

As with other NSAIDs, concomitant treatment with drugs increasing potassium plasma levels, may be associated with increased serum potassium levels and may increase the risk of renal failure

Dexketoprofen [1], diuretics ---> SmPC of [1] of eMC

Dexketoprofen may reduce the effect of diuretics

Dexketoprofen, potassium-sparing diuretics

The co-administration may decrease the diuretic effect, increase the risk of renal failure due to a reduction in renal blood flow and cause hypercaliemia.

Diazepam [1], diuretics ---> SmPC of [1] of eMC

Enhanced hypotensive effect

Diazoxide, diuretics

Increased hypotensive effect

Diclofenac [1], diuretics ---> SmPC of [1] of eMC

Reduced diuretic effect. Diuretics can increase the risk of nephrotoxicity of NSAIDs

Diclofenac, potassium-sparing diuretics

The co-administration may decrease the diuretic effect, increase the risk of renal failure due to a reduction in renal blood flow and cause hypercaliemia.

Digital glycosides, diuretics ---> SmPC of [metildigoxin] of eMC

Electrolyte imbalance may increase the toxicity of cardiac glycosides

Digitoxin, diuretics

Increased effect of digitoxin and risk of digitoxin intoxication due to drug-induced hypokaliemia and hypomagnesemia

Digitoxin, potassium-sparing diuretics

The co-administration may decrease the positive inotrope effect of digitoxin and promote heart rhythm disorders

Digoxin [1], diuretics ---> SmPC of [1] of eMC

Agents causing hypokalaemia or intracellular potassium deficiency may cause increased sensitivity to digoxin

Digoxin [1], loop diuretics ---> SmPC of [1] of eMC

Agents causing hypokalaemia or intracellular potassium deficiency may cause increased sensitivity to digoxin

Digoxin, potassium-sparing diuretics

The co-administration may decrease the positive inotrope effect of digoxin and promote heart rhythm disorders

Dihydralazine, diuretics

The co-administration may increase the hypotensive effect

Diltiazem, diuretics

Diltiazem may enhance the effect of co-administered antihypertensive agents

Dimenhydrinate, non-potassium-sparing diuretics

The concurrent use of dimenhydrinate and drugs that can cause hypokaliemia should be avoided

Dimethyl fumarate [1], diuretics ---> SmPC of [1] of EMA

Concurrent therapy of dimethyl fumarate with nephrotoxic medicinal may increase the potential of renal adverse reactions (e.g. proteinuria)

Disopyramide [1], diuretics ---> SmPC of [1] of eMC

Concomitant use of disopyramide with drugs can induce hypokalaemia may reduce the action of the drug, or potentiate proarrhythmic effects

Diuretics [1], methyldopa ---> SmPC of [1] of eMC

Concomitant use of methyldopa and diuretics may enhance the hypotensive effect.

Diuretics [1], pholcodine ---> SmPC of [1] of eMC

The reduction of blood pressure caused by diuretics may accentuate the hypotensive effects of pholcodine.

Diuretics, dopamine [2] ---> SmPC of [2] of eMC

Dopamine may increase the effect of diuretic agents.

Diuretics, droperidol [2] ---> SmPC of [2] of eMC

To prevent QT prolongation, caution is necessary when patients are taking medicinal products likely to induce electrolyte imbalance

Diuretics, empagliflozin/metformin [2] ---> SmPC of [2] of EMA

Glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed

Diuretics, enalapril [2] ---> SmPC of [2] of eMC

ACE inhibitors attenuate diuretic induced potassium loss.

Diuretics, ephedrine

Furosemide and other diuretics may decrease the pressor response of ephedrine

Diuretics, epinephrine [2] ---> SmPC of [2] of eMC

Drugs which cause potassium loss (corticosteroids, potassium-depleting diuretic, aminophylline, theophylline) increase the risk of hypokalemia.

Diuretics, eplerenone [2] ---> SmPC of [2] of eMC

Potassium-sparing diuretics may potentiate the effect of other diuretics.

Diuretics, ertugliflozin/metformin [2] ---> SmPC of [2] of EMA

Ertugliflozin may add to the diuretic effect of diuretics and may increase the risk of dehydration and hypotension

Diuretics, estrogens

Effects of diuretics are antagonized by oestrogens

Diuretics, etoricoxib [2] ---> SmPC of [2] of eMC

NSAIDs may reduce the effect of diuretics drugs

Diuretics, felodipine [2] ---> SmPC of [2] of eMC

Due to an initial saliuretic effect, felodipine can enhance a pre-existing hypokalemia when added to diuretic therapy.

Diuretics, fenoterol

The co-administration may cause a severe hypokaliemia

Diuretics, flecainide [2] ---> SmPC of [2] of eMC

Class effect due to hypokalaemia giving rise to cardiotoxicity.

Diuretics, fludrocortisone

Corticosteroids antagonise the effects of diuretics. The hypokalaemic effect of diuretics is enhanced.

Diuretics, flurbiprofen [2] ---> SmPC of [2] of eMC

NSAIDs may reduce the effect of diuretics

Diuretics, formoterol [2] ---> SmPC of [2] of eMC

Concomitant treatment may potentiate a possible hypokalaemic effect of beta2-agonists.

Diuretics, fosinopril [2] ---> SmPC of [2] of eMC

Combination with of fosinopril with other anti-hypertensive agents may increase the anti-hypertensive effect.

Diuretics, furosemide [2] ---> SmPC of [2] of eMC

A marked fall in blood pressure and deterioration in renal function

Diuretics, gallopamil

Enhancement of hypotensive effect

Diuretics, glibenclamide [2] ---> SmPC of [2] of EMA

The co-administration may weaken the hypoglycemic effect

Diuretics, gliquidone

Hyperglycemic reactions may occur as expression of weakening effect of gliquidone with gliquidone is co-administered with diuretics

Diuretics, glucocorticoids

The effects of diuretics are antagonised by glucocorticoids

Diuretics, glycerol trinitrate [2] ---> SmPC of [2] of eMC

Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.

Diuretics, glycerol trinitrate [2] ---> SmPC of [2] of eMC

Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.

Diuretics, hydralazine

The co-administration may increase the hypotensive effect

Diuretics, hydrochlorothiazide

Increased hypotensive effect.

Diuretics, hyponatremia

The hyponatraemic effect of diuretics may be intensified by concomitant administration

Diuretics, ibuprofen [2] ---> SmPC of [2] of EMA

Ibuprofen may reduce the effect of diuretics; diuretics can increase the risk of nephrotoxicity of NSAIDs in dehydrated patients.

Diuretics, ibutilide

The co-administration may cause hypokaliemia and/or hypomagnesemia

Diuretics, imipramine [2] ---> SmPC of [2] of eMC

Concurrent use of a tricyclic antidepressant and a diuretic may increase the risk of postural hypotension.

Diuretics, indapamide [2] ---> SmPC of [2] of eMC

The co-administration of indapamide with diuretics which may cause hypokalaemia is not recommended.

Diuretics, insulin

Possible increase of the insulin requirements

Diuretics, insulin glargin [2] ---> SmPC of [2] of EMA

Reduced blood-glucose-lowering effect

Diuretics, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA

This substance may reduce the blood-glucose-lowering effect.

Diuretics, insulin glulisin [2] ---> SmPC of [2] of EMA

Possible decrease in blood-glucose-lowering activity

Diuretics, iobitridol

Risk of acute renal failure. Previous hydroelectric rehydratation is recommended

Diuretics, iodinated contrast media ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be rehydrated before administration.

Diuretics, iomeprol [2] ---> SmPC of [2] of eMC

It has been reported that cardiac and/or hypertensive patients under treatment with diuretics, ACE-inhibitors, and/or beta blocking agents are at higher risk of adverse reactions when administered iodinated contrast media.

Diuretics, iopamidol ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA

In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be rehydrated before administration.

Diuretics, ioxaglic acid

Risk of acute renal failure. Previous hydroelectric rehydratation is recommended

Diuretics, irbesartan [2] ---> SmPC of [2] of EMA

Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with irbesartan

Diuretics, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with irbesartan

Diuretics, isocarboxazid

Concurrent administration of isocarboxazid with diuretics may lead to potentiation of their effects.

Diuretics, isosorbide dinitrate [2] ---> SmPC of [2] of eMC

Concurrent intake of drugs with blood pressure lowering properties may potentiate the hypotensive effect

Diuretics, ivabradine [2] ---> SmPC of [2] of EMA

In pivotal phase III clinical trials diuretics were routinely combined with ivabradine with no evidence of safety concerns

Diuretics, kebuzone

Reduced diuretic and antihypertensive effect of diuretic (decreased natriuresis and water excretion)

Diuretics, ketoprofen [2] ---> SmPC of [2] of eMC

Risk of reduced diuretic effect. Patients and particularly dehydrated patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.

Diuretics, ketorolac [2] ---> SmPC of [2] of eMC

NSAIDs may reduce the effect of diuretics medicinal products.

Diuretics, labetalol

Possible enhancement of hypotensive effect of labetalol

Diuretics, lacidipine [2] ---> SmPC of [2] of eMC

Co-administration of lacidipine with other agents recognised to have a hypotensive effect may have an additive hypotensive effect.

Diuretics, laxatives

Increased potassium loss

Diuretics, lercanidipine [2] ---> SmPC of [2] of eMC

Lercanidipine has been safely administered with diuretics and ACE inhibitors.

Diuretics, levacetylmethadol

Medicinal products known to induce low blood salts must never be taken during the course of levacetylmethadol treatment

Diuretics, linagliptin/metformin [2] ---> SmPC of [2] of EMA

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also hyperglycemic effect.

Diuretics, lisinopril [2] ---> SmPC of [2] of eMC

When a diuretic is added to the therapy of a patient receiving lisinopril the antihypertensive effect is usually additive.

Diuretics, lithium

Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity; concomitant use is not recommended.

Diuretics, lithium carbonate

Serum lithium levels may be increased

Diuretics, lofepramine

Postural hypotension is associated with lofepramine when administered with diuretics

Diuretics, lorazepam [2] ---> SmPC of [2] of eMC

Enhanced hypotensive effect

Diuretics, lumiracoxib

Reduced diuretic and antihypertensive effect of diuretic. Diuretic can increase the risk of nephrotoxicity of the NSAID

Diuretics, lymecycline

The co-administration may enhance the nephrotoxicity of the tetracycline

Diuretics, manidipine

The antihypertensive effect of manidipine can be enhanced by the co-administration of diuretics

Diuretics, mefruside

The co-administration may increase the antihypertensive effects

Diuretics, meglumine and sodium ioxitalamate

Additive diuretic effect due to hyperosmolar properties of the contrast medium. Possible decrease of renal function until permanent damage

Diuretics, meloxicam

The treatment of diuretic agents with meloxicam is associated with a risk of acute renal failure especially by dehydrated patients

Diuretics, metformin

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also hyperglycemic effect.

Diuretics, metformin/saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA

Glucocorticoids (given by systemic and local routes), beta-2 agonists, and diuretics have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed

Diuretics, methylprednisolone

Increased potassium elimination

Diuretics, metildigoxin

Electrolyte imbalance may increase the toxicity of cardiac glycosides

Diuretics, midazolam

Enhanced hypotensive effect

Diuretics, mifamurtide

Caution should be exercised when starting concomitant use of mifamurtide with antihypertensives and patients should be monitored for possible adverse reactions.

Diuretics, milrinone

Improvement in cardiac output with resultant diuresis may necessitate a reduction in the dose of diuretic. Potassium loss due to excessive diuresis may necessitate a reduction in the dose of diuretic.

Diuretics, minocycline

Diuretics may aggravate nephrotoxicity by volume depletion.

Diuretics, minoxidil

The salt and water retention by minoxidil may be limited by diuretic agent

Diuretics, mivacurium [2] ---> SmPC of [2] of eMC

As all non-depolarising neuromuscular blocking agents, the magnitude and/or duration of non-depolarising neuromuscular block may be increased and infusion requirements may be reduced as a result of interaction with diuretics

Diuretics, moexipril

Excessive reductions in blood pressure, especially in patients in whom diuretic therapy was recently instituted, have been reported with ACE inhibitors.

Diuretics, muscle relaxants (non-depolarizing) ---> SmPC of [atracurium] of eMC

As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with diuretics

Diuretics, nabumetone [2] ---> SmPC of [2] of eMC

Diuretics and other antihypertensives drugs may present with decreased effect when concomitantly administered with NSAID

Diuretics, nadolol [2] ---> SmPC of [2] of eMC

Nadolol with antihypertensives may cause an additive hypotensive effect.

Diuretics, naproxen [2] ---> SmPC of [2] of eMC

NSAIDs may reduce the effect of diuretics and antihypertensive medicinal products.

Diuretics, nateglinide [2] ---> SmPC of [2] of EMA

Diuretics may reduce the hypoglycaemic effect of nateglinide

Diuretics, neuroleptics ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

The hyponatraemic effect of diuretics may be intensified by concomitant administration of neuroleptics. Caution is indicated in long-term administration of these medicinal products.

Diuretics, nicardipine [2] ---> SmPC of [2] of eMC

If used nicardipine in combination with diuretics or beta-blockers, careful titration of nicardipine is advised.

Diuretics, nifedipine [2] ---> SmPC of [2] of eMC

Nifedipine may be used in combined therapy with other antihypertensive agents including beta-blocker drugs, but the possibility of an additive effect resulting in postural hypotension should be borne in mind.

Diuretics, nimesulide

Reduced diuretic and antihypertensive effect of diuretic

Diuretics, nimodipine [2] ---> SmPC of [2] of eMC

Nimodipine may increase the blood pressure lowering effect of concomitant antihypertensives

Diuretics, nisoldipine

The co-administration may potentiate the hypotensive effect

Diuretics, nitrendipine

The co-administration may potentiate the hypotensive effect

Diuretics, noradrenaline

Possible severe, prolonged hypertension and heart rhythm disorders. The combination is not recommended

Diuretics, norepinephrine

Possible severe, prolonged hypertension and heart rhythm disorders. The combination is not recommended

Diuretics, NSAID ---> SmPC of [parecoxib] of EMA

NSAIDs may reduce the effect of diuretics.

Diuretics, olmesartan medoxomil [2] ---> SmPC of [2] of eMC

The blood pressure lowering effect of olmesartan medoxomil can be increased by concomitant use of other antihypertensive medications.

Diuretics, olmesartan medoxomil/amlodipine [2] ---> SmPC of [2] of eMC

The blood pressure lowering effect of olmesartan medoxomil/amlodipine can be increased by concomitant use of other antihypertensive medicinal products

Diuretics, oral anticoagulants

The co-administration may decrease the anticoagulant effect

Diuretics, oxaprozin

Reduced diuretic and antihypertensive effect of diuretic. Diuretic can increase the risk of nephrotoxicity of the NSAID

Diuretics, oxprenolol

The co-administration may enhance the hypotensive effect

Diuretics, oxytetracycline

The nephrotoxic effects of tetracyclines may be exacerbated by co-administration of diuretics

Diuretics, pancuronium [2] ---> SmPC of [2] of eMC

Potentiation of the duration of action of pancuronium and the intensity of neuromuscular block.

Diuretics, parecoxib [2] ---> SmPC of [2] of EMA

Inhibition of prostaglandins by NSAIDs, including COX-2 inhibitors, may diminish the effect of diuretics

Diuretics, pentaerythritol tetranitrate

The co-administration may potentiate the hypotensive effect

Diuretics, perindopril

The co-administration may enhance the hypotensive effect

Diuretics, phenprocoumon

Weakening of phenprocoumon effect with the use concomitant or prior of diuretics

Diuretics, phenylbutazone

Phenylbutazone may weaken the effect of diuretic agents

Diuretics, pimozide [2] ---> SmPC of [2] of eMC

Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

Diuretics, pindolol

Concomitant use of beta-blockers with diuretics may increase the blood pressure lowering effect.

Diuretics, pindolol/clopamide

Concomitant use of pindolol/clopamide and diuretic agents may increase the blood pressure lowering effect.

Diuretics, pioglitazone/metformin [2] ---> SmPC of [2] of EMA

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also hyperglycemic effect.

Diuretics, piretanide

The co-administration of piretanide with other diuretic agents may potentiate the diuretic effect and cause marked hypotension

Diuretics, piroxicam

Reduced diuretic and antihypertensive effect of diuretic. Diuretic can increase the risk of nephrotoxicity of the NSAID

Diuretics, potassium canrenoate

Increased diuretic effect

Diuretics, potassium-sparing diuretics ---> SmPC of [eplerenone] of eMC

Potassium-sparing diuretics may potentiate the effect of other diuretics.

Diuretics, prazosin

The co-administration may enhance the hypotensive effect

Diuretics, prednisolone

The co-administration may increase the risk of hypokalaemia.

Diuretics, probenecide

The co-administration may decrease or abolish the effect of probenecid

Diuretics, proglumetacine

Reduced diuretic and antihypertensive effect of diuretic. Diuretic can increase the risk of nephrotoxicity of the NSAID

Diuretics, propranolol [2] ---> SmPC of [2] of EMA

When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.

Diuretics, prothipendyl

Concomitant use of prothipendyl with drugs that can cause hypokaliemia should be avoided

Diuretics, proton pump inhibitors ---> SmPC of [lansoprazole] of eMC

For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia, health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment

Diuretics, pyrazolones

The co-administration may change the effect of diuretic agent

Diuretics, quinapril [2] ---> SmPC of [2] of eMC

Patients treated with diuretics may occasionally experience an excessive reduction of blood pressure after initiation of therapy with quinapril

Diuretics, ramipril [2] ---> SmPC of [2] of eMC

Potentiation of the risk of hypotension is to be anticipated. Caution is recommended

Diuretics, reproterol

The co-administration of diuretics and high doses of reproterol may cause intense hypokaliemia

Diuretics, rocuronium [2] ---> SmPC of [2] of eMC

Increased rocuronium effects

Diuretics, salbutamol [2] ---> SmPC of [2] of eMC

Owing to the hypokalaemic effect of beta-agonists, co-administration of serum potassium depleting agents known to exacerbate the risk of hypokalaemia should be administered cautiously after careful evaluation of the benefits and risks

Diuretics, salicylates

Salicylate may reduce the effect of diuretics.

Diuretics, salmeterol [2] ---> SmPC of [2] of eMC

Particular caution is advised in acute severe asthma as hypokalaemia may be potentiated by concomitant treatment with diuretics.

Diuretics, salmeterol/fluticasone propionate [2] ---> SmPC of [2] of EMA

Potentially serious hypokalaemia may result from beta2 agonist therapy. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics.

Diuretics, saxagliptin/metformin [2] ---> SmPC of [2] of EMA

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also intrinsic hyperglycaemic activity.

Diuretics, sertraline [2] ---> SmPC of [2] of EMA

The co-administration increases the risk of hyponatremia

Diuretics, sildenafil [2] ---> SmPC of [2] of EMA

Population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as thiazide and related diuretics, loop and potassium sparing diuretics

Diuretics, sitagliptin/metformin [2] ---> SmPC of [2] of EMA

Glucocorticoids (given by systemic and local routes) beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed

Diuretics, sodium picosulfate [2] ---> SmPC of [2] of eMC

The concomitant use of diuretics may increase the risk of electrolyte imbalance if excessive doses of picosulfate are taken.

Diuretics, spirapril

Increased hypotensive effect.

Diuretics, spironolactone

The co-administration of spironolactone and other diuretic agents may enhance the diuretic effect and cause a significant hypotension

Diuretics, talinolol

The co-administration may cause a pronounced hypotension

Diuretics, tenoxicam [2] ---> SmPC of [2] of eMC

Non-steroidal anti-inflammatory drugs may cause sodium, potassium and fluid retention and may interfere with the natriuretic action of diuretic agents, which can increase the risk of nephrotoxicity of NSAIDs.

Diuretics, terbutaline [2] ---> SmPC of [2] of eMC

Hypokalaemia may result from beta2-agonist therapy and may be potentiated by concomitant treatment with diuretics

Diuretics, terfenadine

Hypokalaemia or other electrolyte imbalance increases the risk of ventricular arrhythmias with terfenadine.

Diuretics, tetracosactide

Increased potassium elimination by diuretics/saluretics

Diuretics, tetracyclines

The nephrotoxic effects of tetracyclines may be exacerbated by co-administration of diuretics

Diuretics, theophylline

Theophylline enhances the diuretic effect

Diuretics, thiazides

The co-administration may increase the antihypertensive effects

Diuretics, tiaprofenic acid

Caution must be exercised when tiaprofenic acid is given with diuretics, it reduces the diuretic and antihypertensive effect of diuretics and increase risk of renal impairment and/or hyperkalemia

Diuretics, tizanidine [2] ---> SmPC of [2] of eMC

As tizanidine may induce hypotension it may potentiate the effect of antihypertensive products, including diuretics, and caution should therefore be exercised in patients receiving blood pressure lowering products.

Diuretics, tobramycin [2] ---> SmPC of [2] of EMA

Concomitant use of tobramycin with diuretic compounds is not recommended. Such compounds can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.

Diuretics, trandolapril [2] ---> SmPC of [2] of eMC

Combination of trandolapril with diuretics may potentiate the antihypertensive response to trandolapril

Diuretics, trandolapril/verapamil [2] ---> SmPC of [2] of eMC

Patients on diuretics and especially those who are volume-and / or salt depleted may experience an excessive reduction of blood pressure after initiation of therapy with an ACE inhibitor.

Diuretics, treprostinil

Concomitant administration of treprostinil with diuretics, antihypertensive agents or other vasodilators increases the risk of systemic hypotension.

Diuretics, triamterene/hydrochlorothiazide

The antihypertensive effect of triamterene/hydrochlorothiazide may be enhanced by other diuretic agents

Diuretics, tricyclic antidepressant ---> SmPC of [imipramine] of eMC

Concurrent use of a tricyclic antidepressant and a diuretic may increase the risk of postural hypotension.

Diuretics, trimethoprim

In elderly patients taking diuretics, particularly thiazides, there is an increased incidence of thrombocytopaenia with purpura.

Diuretics, urapidil

The antihypertensive effect of urapidil may be enhanced with the concomitant use of other antihypertensive drugs

Diuretics, valdecoxib

Decreased diuretic effect. The risk of acute renal insufficiency may be increased

Diuretics, vardenafil [2] ---> SmPC of [2] of EMA

Population pharmacokinetic analysis showed no effect on vardenafil pharmacokinetics of both medicinal products concomitant administered

Diuretics, verapamil [2] ---> SmPC of [2] of eMC

Potentiation of the hypotensive effect

Diuretics, vildagliptin/metformin [2] ---> SmPC of [2] of EMA

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also hyperglycemic effect.

Diuretics, xipamide [2] ---> SmPC of [2] of eMC

The dosage of other hypotensive drugs may require adjustment when used in conjunction with xipamide

Diuretics, zoledronate

Caution is indicated when zoledronate is administered in conjunction with medicinal products that can significantly impact renal function

Doxepin, non-potassium-sparing diuretics

The co-administration of doxepin with medicinal products that can cause hypokaliemia should be avoided

Droperidol [1], non-potassium-sparing diuretics ---> SmPC of [1] of eMC

To prevent QT prolongation, caution is necessary when patients are taking medicinal products likely to induce electrolyte imbalance

Drospirenone, potassium-sparing diuretics

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Drospirenone/estetrol [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of Drovelis with aldosterone antagonists or potassium-sparing diuretics has not been studied. In this case, serum potassium should be tested during the first treatment cycle.

Empagliflozin [1], loop diuretics ---> SmPC of [1] of EMA

Empagliflozin may add to the diuretic effect of loop diuretics and may increase the risk of dehydration and hypotension

Empagliflozin/linagliptin [1], loop diuretics ---> SmPC of [1] of EMA

Empagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension

Empagliflozin/metformin [1], loop diuretics ---> SmPC of [1] of EMA

Empagliflozin may add to the diuretic effect of loop diuretics and may increase the risk of dehydration and hypotension

Enalapril [1], loop diuretics ---> SmPC of [1] of eMC

Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with enalapril

Enalapril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.

Enalapril/hydrochlorothiazide [1], loop diuretics ---> SmPC of [1] of eMC

Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with enalapril

Enalapril/hydrochlorothiazide [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

ACE inhibitors attenuate diuretic induced potassium loss. Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.

Enoxaparin sodium [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Heparin can suppress adrenal secretion of aldosterone leading to hyperkalaemia

Eplerenone [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Due to increased risk of hyperkalaemia, eplerenone should not be administered to patients receiving other potassium-sparing diuretics and potassium supplements

Eprosartan [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of eprosartan with K-sparing diuretics, K-supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increase in serum potassium.

Ertugliflozin/metformin [1], loop diuretics ---> SmPC of [1] of EMA

Some medicinal products can adversely affect renal function, which may increase the risk of lactic acidosis

Escitalopram [1], non-potassium-sparing diuretics ---> SmPC of [1] of eMC

Caution is warranted for concomitant use of escitalopram with hypokalaemia/hypomagnesaemia inducing medicinal products as these conditions increase the risk of malignant arrhythmias

Ethinylestradiol/drospirenone [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of ethinylestradiol/drospirenone with aldosterone antagonists or potassium-sparing diuretics has not been studied. In this case, serum potassium should be tested during the first treatment cycle.

Felodipine/ramipril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

The combination may increase the serum potassium concentration and requires close monitoring of serum potassium. The combination is not recommended

Flecainide [1], loop diuretics ---> SmPC of [1] of eMC

Class effect due to hypokalaemia giving rise to cardiotoxicity.

Fludrocortisone, loop diuretics [2] ---> SmPC of [2] of eMC

Corticosteroids antagonise the effects of diuretics. The hypokalaemic effect of diuretics is enhanced.

Flupentixol, non-potassium-sparing diuretics

Drugs known to cause electrolyte disturbances such as thiazide diuretics (hypokalaemia) should also be used with caution as they may increase the risk of QT prolongation and malignant arrythmias

Flurbiprofen [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia

Fluticasone furoate/umeclidinium/vilanterol [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore caution should be exercised

Formoterol [1], loop diuretics ---> SmPC of [1] of eMC

Concomitant treatment may potentiate a possible hypokalaemic effect of beta2-agonists.

Formoterol/glycopyrronium/budesonide [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Possible initial hypokalaemia may be potentiated by concomitant medicinal products, including xanthine derivatives, steroids and non-potassium sparing diuretics

Fosinopril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.

Gentamicin [1], loop diuretics ---> SmPC of [1] of eMC

Potent diuretics are believed to enhance the risk of ototoxicity

Gentamicin [1], strong diuretic agents ---> SmPC of [1] of eMC

Potent diuretics are believed to enhance the risk of ototoxicity

Glimepiride [1], loop diuretics ---> SmPC of [1] of eMC

Weakening of the blood-glucose-lowering effect and possible hyperglycaemia

Glimepiride [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Weakening of the blood-glucose-lowering effect and possible hyperglycaemia

Glucocorticoids, loop diuretics ---> SmPC of [deflazacort] of eMC

Hypokalaemic effects of loop diuretics are enhanced by corticosteroids.

Glycopyrronium/formoterol [1], non-potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible initial hypokalaemic effect of beta2-adrenergic agonists, therefore, caution is advised in their concomitant use

Glycopyrronium/indacaterol/mometasone [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Hydroquinidine, non-potassium-sparing diuretics

Concomitant use of hydroquinidine and hypokalaemic agents increases the risk of heart rhythm disorders (torsades de pointes)

Hyperkalemia, potassium-sparing diuretics

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Hypokalemia, non-potassium-sparing diuretics ---> SmPC of [indacaterol/glycopyrronium] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Hypokalemia, potassium-sparing diuretics

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Hypokalemia, potassium-sparing diuretics ---> SmPC of [glycopyrronium/indacaterol/mometasone] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Ibuprofen, potassium-sparing diuretics ---> SmPC of [amiloride/hydrochlorothiazide] of eMC

Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia

Imidapril [1], loop diuretics ---> SmPC of [1] of eMC

Risk of sudden hypotension and/or acute renal impairment on initiation of treatment with an ACE inhibitor in patients with pre-existing salt/volume depletion.

Imidapril [1], non-potassium-sparing diuretics ---> SmPC of [1] of eMC

Risk of sudden hypotension and/or acute renal impairment on initiation of treatment with an ACE inhibitor in patients with pre-existing salt/volume depletion.

Imidapril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Potassium sparing diuretics or supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium (potentially lethal), mainly in conjunction with renal impairment (additive hyperkaliemic effects)

Indacaterol [1], loop diuretics ---> SmPC of [1] of EMA

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect indacaterol. Use with caution

Indapamide [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Whilst rational combinations are useful in some patients, hypokalaemia or hyperkalaemia (particularly in patients with renal failure or diabetes) may still occur. Plasma potassium and ECG should be monitored and, if necessary, treatment re

Indapamide, loop diuretics [2] ---> SmPC of [2] of eMC

The co-administration of indapamide with diuretics which may cause hypokalaemia is not recommended.

Indometacin, potassium-sparing diuretics [2] ---> SmPC of [2] of eMC

Indometacin and potassium-sparing diuretics each may be associated with increased plasma potassium levels. The potential effects of indometacin and potassium-sparing diuretics on potassium kinetics and renal function should be considered

Irbesartan [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of irbesartan und potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels is not recommended

Irbesartan/hydrochlorothiazide [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Ivabradine [1], loop diuretics ---> SmPC of [1] of EMA

Hypokalemia can increase the risk of arrhythmia. As ivabradine may cause bradycardia, the resulting combination of hypokalemia and bradycardia is a predisposing factor to the onset of severe arrhythmias, especially in patients with long QT syndrome

Kebuzone, potassium-sparing diuretics

Possible hyperkaliemia

Ketoprofen [1], loop diuretics ---> SmPC of [1] of eMC

Risk of reduced diuretic effect. Patients and particularly dehydrated patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.

Ketoprofen, potassium-sparing diuretics

The co-administration may decrease the diuretic effect, increase the risk of renal failure due to a reduction in renal blood flow and cause hypercaliemia.

Lactulose, non-potassium-sparing diuretics

Lactulose may enhance other drug-induced hypokalemia

Laxatives, loop diuretics

Additional potasium loss

Levomepromazine, non-potassium-sparing diuretics

Avoid concomitant neuroleptics and any other drugs that may cause electrolyte imbalance. Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

Lisinopril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes, particularly in patients with impaired renal function, may lead to a significant increase in serum potassium.

Lisinopril/hydrochlorothiazide [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

The use of potassium supplements, potassium-sparing agents or potassium-containing salt substitutes, particularly in patients with impaired renal function or diabetes mellitus, may lead to a significant increase in serum potassium.

Lithium, loop diuretics [2] ---> SmPC of [2] of eMC

Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity; concomitant use is not recommended.

Lithium, osmotic diuretics

The combination may decrease serum lithium levels due to an increase in lithium renal clearance

Lithium, potassium-sparing diuretics [2] ---> SmPC of [2] of eMC

Lithium should not generally be given with diuretics because they reduce it renal clearance and add a high risk of lithium toxicity.

Loop diuretics, lornoxicam

Decreased diuretic and antihypertensive effect of loop diuretics

Loop diuretics, metformin

Diuretics may increase the risk of lactic acidosis due to their potential to decrease renal function. Diuretics have also hyperglycemic effect.

Loop diuretics, metformin/saxagliptin/dapagliflozin

Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension

Loop diuretics, metformin/saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA

Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis. When starting or using such product in combination with metformin, close monitoring of renal function is necessary.

Loop diuretics, methotrexate

Possible decrease of tubular secretion of methotrexate

Loop diuretics, metolazone

The co-administration may potentiate significantly the effect of metolazone and cause severe electrolyte imbalances

Loop diuretics, mineralocorticoids

Additional potasium loss or hypokaliemia

Loop diuretics, moxifloxacin [2] ---> SmPC of [2] of eMC

Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels

Loop diuretics, neomycin

The co-administration may enhance the nephrotoxicity and/or ototoxicity

Loop diuretics, nephrotoxic substances

The co-administration may enhance the nephrotoxicity

Loop diuretics, noradrenaline

Decreased effect of pressor amine

Loop diuretics, NSAID

The co-administration may decrease the diuretic effect and increase the risk of renal failure secondary to a reduction in renal blood flow.

Loop diuretics, ototoxic agents

The co-administration may enhance the ototoxicity

Loop diuretics, paracetamol

The effects of diuretic agents may be decreased due to paracetamol may decrease the renal excretion of prostaglandins and the activity of the plasmatic renin

Loop diuretics, pemetrexed [2] ---> SmPC of [2] of EMA

Concomitant administration of nephrotoxic can potentially delay the clearance of pemetrexed. The combination should be used with caution

Loop diuretics, perindopril [2] ---> SmPC of [2] of eMC

Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor.

Loop diuretics, phenylbutazone

Phenylbutazone may weaken the effect of diuretic agents

Loop diuretics, pioglitazone/glimepiride [2] ---> SmPC of [2] of EMA

Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur

Loop diuretics, prednisolone

The co-administration may enhance the additional potassium elimination

Loop diuretics, prednisone [2] ---> SmPC of [2] of eMC

Potassium excretion is enhanced.

Loop diuretics, probenecide

Probenecid can decrease the effect of high-ceiling diuretic

Loop diuretics, reboxetine [2] ---> SmPC of [2] of eMC

The possibility of hypokalaemia with concomitant use of potassium losing diuretics should be considered.

Loop diuretics, ritodrine

Possible hypokaliemia

Loop diuretics, salicylates

Enhanced toxic effect of salicylate (at high dose) on the CNS

Loop diuretics, saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA

Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension

Loop diuretics, sulfonylureas

Weakening of the blood-glucose-lowering effect and possible hyperglycaemia

Loop diuretics, telbivudine [2] ---> SmPC of [2] of EMA

Since telbivudine is eliminated primarily by renal excretion, co-administration with substances that affect renal function may affect plasma concentrations of telbivudine and/or the co-administered substance. The combination should be used with caution.

Loop diuretics, telmisartan [2] ---> SmPC of [2] of EMA

Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion and in a risk of hypotension when initiating therapy with telmisartan.

Loop diuretics, tolvaptan [2] ---> SmPC of [2] of EMA

If dehydration or renal dysfunction becomes evident, take appropriate action

Loop diuretics, trandolapril

Trandolapril may attenuate the potassium loss caused by loop diuretic and may increase the hypotensive effect

Loop diuretics, triamcinolone acetonide

Patients should be observed for hypokalaemia.

Loop diuretics, triamcinolone [2] ---> SmPC of [2] of eMC

Patients should be observed for hypokalaemia.

Loop diuretics, vasodilators

Enhancement of hypotensive effect

Loop diuretics, xipamide

The co-administration increases the risk of fluid and electrolyte imbalance disorders

Loop diuretics, zofenopril

Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with zofenopril

Loop diuretics, zoledronic acid [2] ---> SmPC of [2] of EMA

Caution is advised when bisphosphonates are administered with loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required

Lornoxicam, potassium-sparing diuretics

Decreased diuretic and antihypertensive effect of potassium-sparing diuretics

Losartan [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of other drugs which retain potassium or may increase potassium levels, potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium. Co-medication is not advisable.

Losartan/hydrochlorothiazide [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium Co-medication is not advisable.

Lumiracoxib, potassium-sparing diuretics

The co-administration may decrease the diuretic effect, increase the risk of renal failure due to a reduction in renal blood flow and cause hypercaliemia.

Melperone, non-potassium-sparing diuretics

The co-administration of melperone with drugs that can cause hypokaliemia should be avoided

Moclobemide, non-potassium-sparing diuretics

The co-administration of moclobemide with medicinal products that can cause hypokaliemia should be avoided

Moexipril, potassium-sparing diuretics

Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.

Nabumetone [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Hyperkalaemia might develop, particularly with concomitant potassium-sparing diuretics administration.

Nephrotoxic substances, strong diuretic agents

Bumetanide should be used with caution in patients already receiving nephrotoxic or ototoxic drugs.

Non-potassium-sparing diuretics, nortriptyline

The co-administration of nortriptyline with drugs that can cause hypokaliemia should be avoided

Non-potassium-sparing diuretics, perazine

The co-administration of perazine with drugs that can cause hypokaliemia should be avoided

Non-potassium-sparing diuretics, perphenazine

Concomitant use of perphenazine with drugs causing electrolyte imbalance is not recommended.

Non-potassium-sparing diuretics, phenothiazines

Diuretic-induced hypokalaemia may potentiate phenothiazine-induced cardiotoxicity.

Non-potassium-sparing diuretics, pimozide

The co-administration of pimozide with medicinal products that cause hypokaliemia should be avoided

Non-potassium-sparing diuretics, platinum compounds

Hypokalaemia caused by diuretics increases risk of ventricular arrhythmias with platinum compounds.

Non-potassium-sparing diuretics, promazine

Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

Non-potassium-sparing diuretics, promethazine

The co-administration of promethazine with drugs that may cause hypokaliemia should be avoided

Non-potassium-sparing diuretics, sotalol [2] ---> SmPC of [2] of eMC

With potassium-depleting diuretic may occur hypokalaemia or hypomagnesaemia, increasing the potential for torsade de pointes

Non-potassium-sparing diuretics, sulpiride [2] ---> SmPC of [2] of eMC

The combination of sulpiride with hypokaliemia-inducing medications is not recommended

Non-potassium-sparing diuretics, terfenadine

Hypokalaemia or other electrolyte imbalance increases the risk of ventricular arrhythmias with terfenadine.

Non-potassium-sparing diuretics, terlipressin

Terlipressin can cause ventricular arrhythmias. The combination with drugs that can origin electrolyte disorders should be done with extreme caution

Non-potassium-sparing diuretics, umeclidinium/vilanterol [2] ---> SmPC of [2] of EMA

Concomitant hypokalaemic treatment with non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Non-potassium-sparing diuretics, vilanterol ---> SmPC of [umeclidinium/vilanterol] of EMA

Concomitant hypokalaemic treatment with non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Non-potassium-sparing diuretics, zuclopenthixol [2] ---> SmPC of [2] of eMC

Drugs known to cause electrolyte disturbances such as thiazide diuretics (hypokalemia) should be used with caution as they may increase the risk of QT prolongation and malignant arrhythmias

NSAID, potassium-sparing diuretics ---> SmPC of [amiloride/hydrochlorothiazide] of eMC

Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia, particularly in elderly patients.

NSAID, strong diuretic agents

The co-administration may increase the nephrotoxicity risk. Concomitant use should be avoided

Olmesartan medoxomil [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.

Olmesartan medoxomil/amlodipine [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.

Olmesartan, potassium-sparing diuretics

Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.

Perindopril [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Hyperkalaemia (potentially lethal), especially in conjunction with renal impairment (additive hyperkaliemic effects). The combination is not recommended

Phenylbutazone, potassium-sparing diuretics

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Piroxicam, potassium-sparing diuretics

Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia

Potassium canrenoate, potassium-sparing diuretics

The co-administration of ACE inhibitors with potassium canreonate may result in an increase in serum potassium levels up to life threatening hyperkaliemia. It can also cause acute renal failure

Potassium chloride [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Combined treatment of potassium chloride with potassium sparing diuretics increase the risk of hyperkalaemia

Potassium citrate/potassium hydrogen carbonate [1], potassium-sparing diuretics ---> SmPC of [1] of EMA

Concomitant use of Sibnayal with medicinal products that may increase potassium levels or induce hyperkalaemia necessitates monitoring of potassium plasma levels

Potassium gluconate, potassium-sparing diuretics

The combination may lead to severe hyperkalemia, particularly in renal failure. Co-administration is contraindicated

Potassium iodide [1], potassium-sparing diuretics ---> SmPC of [1] of eMC

Hyperkalaemia results from the interaction between potassium salts and potassium sparing diuretics

Potassium sodium hydrogen citrate, potassium-sparing diuretics

The potassium-sparing diuretic decreases the renal elimination of potassium

Potassium, potassium-sparing diuretics

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Potassium-sparing diuretics [1], trimethoprim ---> SmPC of [1] of eMC

Hyperkalaemia may be exacerbated by concomitant administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.

Potassium-sparing diuretics, proglumetacine

Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia

Potassium-sparing diuretics, quinapril [2] ---> SmPC of [2] of eMC

Concomitant treatments of quinapril with potassium sparing diuretics, potassium supplements or potassium salts should be used with caution and with appropriate monitoring of serum potassium.

Potassium-sparing diuretics, ramipril [2] ---> SmPC of [2] of eMC

Hyperkalaemia may occur, therefore close monitoring of serum potassium is required. Caution is recommended

Potassium-sparing diuretics, reviparin

Caution is recommended when coadministering reviparin with drugs that increase plasma potassium levels

Potassium-sparing diuretics, sacubitril/valsartan [2] ---> SmPC of [2] of EMA

Concomitant use of potassium-sparing diuretics, mineralocorticoid antagonists, potassium supplements, salt substitutes containing potassium or other agents (such as heparin) may lead to increases in serum potassium, and to increases in serum creatinine.

Potassium-sparing diuretics, spirapril

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Potassium-sparing diuretics, spironolactone [2] ---> SmPC of [2] of eMC

Spironolactone should not be administered concurrently with other potassium-sparing diuretics as this may induce hyperkalaemia.

Potassium-sparing diuretics, tacrolimus [2] ---> SmPC of [2] of EMA

As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics should be avoided

Potassium-sparing diuretics, telmisartan [2] ---> SmPC of [2] of EMA

As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia. The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia

Potassium-sparing diuretics, telmisartan/amlodipine ---> SmPC of [telmisartan] of EMA

As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia. The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia

Potassium-sparing diuretics, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Medicinal products that may increase potassium levels or induce hyperkalaemia: Concomitant use of the these medicinal products may lead to increases in serum potassium and is, therefore, not recommended

Potassium-sparing diuretics, tenoxicam [2] ---> SmPC of [2] of eMC

Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia

Potassium-sparing diuretics, trandolapril [2] ---> SmPC of [2] of eMC

Potassium-sparing diuretics or potassium supplements may increase the risk of hyperkalaemia, particularly in renal failure.

Potassium-sparing diuretics, trandolapril/verapamil [2] ---> SmPC of [2] of eMC

Potassium sparing diuretics may lead to significant increases in serum potassium, particularly in the presence of renal function impairment.

Potassium-sparing diuretics, triamterene

The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended

Potassium-sparing diuretics, triamterene/hydrochlorothiazide

The additional administration of other potassium-sparing diuretics with triamterene/hydrochlorothiazide increases the risk of hyperkaliemia

Potassium-sparing diuretics, valsartan [2] ---> SmPC of [2] of eMC

Concomitant use with of valsartan with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended.

Potassium-sparing diuretics, xipamide

The co-administration may cause hypokaliemia or hyperkaliemia

Potassium-sparing diuretics, zofenopril

Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Combination is not recommended